Table 1 Demographic and clinical information of the study sample
Demographic and clinical information | Results |
|---|---|
Age, years, mean (SD) | 40 (16) |
Sex, n (female/male) | 36/26 |
Diagnosis (CD/UC) | 51/11 |
HBI in patients with CD, median (range) | 9.4 (6.8) |
Partial Mayo Score in patients with UC, mean (SD) | 5.6 (2.5) |
CRP in mg/l, mean (SD) | 21.2 (24.8) |
Faecal calprotectin in μg/g, mean (SD) (n = 53) | 365 (282) |
Fatigue (WEIMuS) score, mean (SD) | 31.5 (14.7) |
WEIMuS ≥ 32P., n (%) | 31 (50%) |
Depression (HADS-D) Score, mean (SD) | 6.5 (4.5) |
HADS-D ≥ 10P., n (%) | 18 (29%) |
Current antidepressant use | 4 (6%) |
Current steroid use, n (%) | 21 (34%) |
Current immunomodulatory therapy, n (%) | 13 (21%) |
Of which biological therapy, n | 10 |
Of which TNF-alpha inhibitors, n | 3 |
Of which vedolizumab, n | 5 |
Of which ustekinumab, n | 2 |
Refractory disease course (> 3 prior systemic therapies), n (%) | 22 (35%) |
Prior bowel resection, n (%) | 24 (38%) |
Prior biological therapy, n (%) | 31 (50%) |